Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation

S. T. Sonis, G. Oster, H. Fuchs, L. Bellm, W. Z. Bradford, J. Edelsberg, V. Hayden, J. Eilers, J. B. Epstein, F. G. LeVeque, C. Miller, D. E. Peterson, M. M. Schubert, F. K.L. Spijkervet, M. Horowitz

Research output: Contribution to journalArticle

447 Citations (Scopus)

Abstract

Purpose: To explore the relationship between oral mucositis and selected clinical and economic outcomes in blood and marrow transplant patients. Patients and Methods: Subjects consisted of 92 transplant patients from eight centers who participated in a multinational pilot study of a new oral mucositis scoring system (Oral Mucositis Assessment Scale [OMAS]). In the pilot study, patients were evaluated for erythema and ulceration/pseudomembrane formation beginning on the first day of conditioning and continuing for 28 days. We examined the relationship between patients' peak OMAS scores and days with fever (body temperature > 38.0°C), the occurrence of significant infection, days of total parenteral nutrition (TPN), and days of injectable narcotic therapy (all over 28 days), days in hospital (over 60 days), total hospital charges for the index admission, and vital status at 100 days. Results: Patients' peak OMAS scores spanned the full range of possible values (0 to 5) and were significantly (P < .05) correlated with all of the outcomes of interest except days with fever (P = .21). In analyses controlling for type of graft (autologous v allogeneic) and study center, a 1-point increase in peak OMAS score was associated with (1) 1.0 additional day with fever (P < .01), (2) a 2.1-fold increase in risk of significant infection (P < .01), (3) 2.7 additional days of TPN (P < .0001), (4) 2.6 additional days of injectable narcotic therapy (P < .0001), (5) 2.6 additional days in hospital (P < .01), (6) $25,405 in additional hospital charges (P < .0001), and (7) a 3.9-fold increase in 100-day mortality risk (P < .01). Mean hospital charges were $42,749 higher among patients with evidence of ulceration compared with those without (P = .06). Conclusion: Oral mucositis is associated with significantly worse clinical and economic outcomes in blood and marrow transplantation.

Original languageEnglish (US)
Pages (from-to)2201-2205
Number of pages5
JournalJournal of Clinical Oncology
Volume19
Issue number8
DOIs
StatePublished - Apr 15 2001

Fingerprint

Stomatitis
Hematopoietic Stem Cell Transplantation
Economics
Hospital Charges
Fever
Total Parenteral Nutrition
Narcotics
Transplants
Bone Marrow
Injections
Erythema
Infection
Body Temperature
Transplantation
Mortality
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sonis, S. T., Oster, G., Fuchs, H., Bellm, L., Bradford, W. Z., Edelsberg, J., ... Horowitz, M. (2001). Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. Journal of Clinical Oncology, 19(8), 2201-2205. https://doi.org/10.1200/JCO.2001.19.8.2201

Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. / Sonis, S. T.; Oster, G.; Fuchs, H.; Bellm, L.; Bradford, W. Z.; Edelsberg, J.; Hayden, V.; Eilers, J.; Epstein, J. B.; LeVeque, F. G.; Miller, C.; Peterson, D. E.; Schubert, M. M.; Spijkervet, F. K.L.; Horowitz, M.

In: Journal of Clinical Oncology, Vol. 19, No. 8, 15.04.2001, p. 2201-2205.

Research output: Contribution to journalArticle

Sonis, ST, Oster, G, Fuchs, H, Bellm, L, Bradford, WZ, Edelsberg, J, Hayden, V, Eilers, J, Epstein, JB, LeVeque, FG, Miller, C, Peterson, DE, Schubert, MM, Spijkervet, FKL & Horowitz, M 2001, 'Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation', Journal of Clinical Oncology, vol. 19, no. 8, pp. 2201-2205. https://doi.org/10.1200/JCO.2001.19.8.2201
Sonis, S. T. ; Oster, G. ; Fuchs, H. ; Bellm, L. ; Bradford, W. Z. ; Edelsberg, J. ; Hayden, V. ; Eilers, J. ; Epstein, J. B. ; LeVeque, F. G. ; Miller, C. ; Peterson, D. E. ; Schubert, M. M. ; Spijkervet, F. K.L. ; Horowitz, M. / Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 8. pp. 2201-2205.
@article{27a28d4a67024d89a0415eb365b4b0be,
title = "Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation",
abstract = "Purpose: To explore the relationship between oral mucositis and selected clinical and economic outcomes in blood and marrow transplant patients. Patients and Methods: Subjects consisted of 92 transplant patients from eight centers who participated in a multinational pilot study of a new oral mucositis scoring system (Oral Mucositis Assessment Scale [OMAS]). In the pilot study, patients were evaluated for erythema and ulceration/pseudomembrane formation beginning on the first day of conditioning and continuing for 28 days. We examined the relationship between patients' peak OMAS scores and days with fever (body temperature > 38.0°C), the occurrence of significant infection, days of total parenteral nutrition (TPN), and days of injectable narcotic therapy (all over 28 days), days in hospital (over 60 days), total hospital charges for the index admission, and vital status at 100 days. Results: Patients' peak OMAS scores spanned the full range of possible values (0 to 5) and were significantly (P < .05) correlated with all of the outcomes of interest except days with fever (P = .21). In analyses controlling for type of graft (autologous v allogeneic) and study center, a 1-point increase in peak OMAS score was associated with (1) 1.0 additional day with fever (P < .01), (2) a 2.1-fold increase in risk of significant infection (P < .01), (3) 2.7 additional days of TPN (P < .0001), (4) 2.6 additional days of injectable narcotic therapy (P < .0001), (5) 2.6 additional days in hospital (P < .01), (6) $25,405 in additional hospital charges (P < .0001), and (7) a 3.9-fold increase in 100-day mortality risk (P < .01). Mean hospital charges were $42,749 higher among patients with evidence of ulceration compared with those without (P = .06). Conclusion: Oral mucositis is associated with significantly worse clinical and economic outcomes in blood and marrow transplantation.",
author = "Sonis, {S. T.} and G. Oster and H. Fuchs and L. Bellm and Bradford, {W. Z.} and J. Edelsberg and V. Hayden and J. Eilers and Epstein, {J. B.} and LeVeque, {F. G.} and C. Miller and Peterson, {D. E.} and Schubert, {M. M.} and Spijkervet, {F. K.L.} and M. Horowitz",
year = "2001",
month = "4",
day = "15",
doi = "10.1200/JCO.2001.19.8.2201",
language = "English (US)",
volume = "19",
pages = "2201--2205",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation

AU - Sonis, S. T.

AU - Oster, G.

AU - Fuchs, H.

AU - Bellm, L.

AU - Bradford, W. Z.

AU - Edelsberg, J.

AU - Hayden, V.

AU - Eilers, J.

AU - Epstein, J. B.

AU - LeVeque, F. G.

AU - Miller, C.

AU - Peterson, D. E.

AU - Schubert, M. M.

AU - Spijkervet, F. K.L.

AU - Horowitz, M.

PY - 2001/4/15

Y1 - 2001/4/15

N2 - Purpose: To explore the relationship between oral mucositis and selected clinical and economic outcomes in blood and marrow transplant patients. Patients and Methods: Subjects consisted of 92 transplant patients from eight centers who participated in a multinational pilot study of a new oral mucositis scoring system (Oral Mucositis Assessment Scale [OMAS]). In the pilot study, patients were evaluated for erythema and ulceration/pseudomembrane formation beginning on the first day of conditioning and continuing for 28 days. We examined the relationship between patients' peak OMAS scores and days with fever (body temperature > 38.0°C), the occurrence of significant infection, days of total parenteral nutrition (TPN), and days of injectable narcotic therapy (all over 28 days), days in hospital (over 60 days), total hospital charges for the index admission, and vital status at 100 days. Results: Patients' peak OMAS scores spanned the full range of possible values (0 to 5) and were significantly (P < .05) correlated with all of the outcomes of interest except days with fever (P = .21). In analyses controlling for type of graft (autologous v allogeneic) and study center, a 1-point increase in peak OMAS score was associated with (1) 1.0 additional day with fever (P < .01), (2) a 2.1-fold increase in risk of significant infection (P < .01), (3) 2.7 additional days of TPN (P < .0001), (4) 2.6 additional days of injectable narcotic therapy (P < .0001), (5) 2.6 additional days in hospital (P < .01), (6) $25,405 in additional hospital charges (P < .0001), and (7) a 3.9-fold increase in 100-day mortality risk (P < .01). Mean hospital charges were $42,749 higher among patients with evidence of ulceration compared with those without (P = .06). Conclusion: Oral mucositis is associated with significantly worse clinical and economic outcomes in blood and marrow transplantation.

AB - Purpose: To explore the relationship between oral mucositis and selected clinical and economic outcomes in blood and marrow transplant patients. Patients and Methods: Subjects consisted of 92 transplant patients from eight centers who participated in a multinational pilot study of a new oral mucositis scoring system (Oral Mucositis Assessment Scale [OMAS]). In the pilot study, patients were evaluated for erythema and ulceration/pseudomembrane formation beginning on the first day of conditioning and continuing for 28 days. We examined the relationship between patients' peak OMAS scores and days with fever (body temperature > 38.0°C), the occurrence of significant infection, days of total parenteral nutrition (TPN), and days of injectable narcotic therapy (all over 28 days), days in hospital (over 60 days), total hospital charges for the index admission, and vital status at 100 days. Results: Patients' peak OMAS scores spanned the full range of possible values (0 to 5) and were significantly (P < .05) correlated with all of the outcomes of interest except days with fever (P = .21). In analyses controlling for type of graft (autologous v allogeneic) and study center, a 1-point increase in peak OMAS score was associated with (1) 1.0 additional day with fever (P < .01), (2) a 2.1-fold increase in risk of significant infection (P < .01), (3) 2.7 additional days of TPN (P < .0001), (4) 2.6 additional days of injectable narcotic therapy (P < .0001), (5) 2.6 additional days in hospital (P < .01), (6) $25,405 in additional hospital charges (P < .0001), and (7) a 3.9-fold increase in 100-day mortality risk (P < .01). Mean hospital charges were $42,749 higher among patients with evidence of ulceration compared with those without (P = .06). Conclusion: Oral mucositis is associated with significantly worse clinical and economic outcomes in blood and marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0035870833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035870833&partnerID=8YFLogxK

U2 - 10.1200/JCO.2001.19.8.2201

DO - 10.1200/JCO.2001.19.8.2201

M3 - Article

C2 - 11304772

AN - SCOPUS:0035870833

VL - 19

SP - 2201

EP - 2205

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -